Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Announces

Salt Lake City, Utah--(Newsfile Corp. - July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study

Related Keywords

United States , Salt Lake City , Utah , Francina Agosti , Innov Ophthalmol , Brianm Strem , Utah Newsfile Corp , Kiora Pharmaceuticals , Linkedin , Twitter , Kiora Pharmaceuticals Inc , Nasdaq , Persistent Corneal Epithelial Defect , Chief Executive Officer , Ocular Presentation , Rheumatoid Arthritis , Dihydroorotate Dehydrogenase , Private Securities Litigation Reform Act , Annual Report , Corneal Epithelial Defects , Med Hypothesis Discov Innov , Kiora , Pharmaceuticals , Nnounces , First , Patient , Unrolled , Hase , Study , Valuating , Persistent , Corneal , Epithelial , Defects ,